Diaceutics PLC (DXRX) Fair Value & Analysis
Healthcare · GB · Market cap 123M GBX
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 6 days ago
Share price +2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range £1.12 – £1.75 · fair‑value band £0.2300 – £0.3600 · the £1.45 price screens above the £0.2900 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Diaceutics PLC (DXRX) currently trades at £1.45, while our model-based Fair Value estimate is £0.2900 — implying the stock looks roughly 79.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Diaceutics PLC generated revenue of £38.4M at a net margin of 0.3%. Revenue grew 20.3% year over year. It earns a return on equity of 0.2%. The balance sheet holds a net cash position of £6.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Diaceutics PLC reported revenue of £38.4M in FY2025 versus £13.9M in FY2021, a compound +28.9%/yr. Reported net income was £97.0K in FY2025, compounding −35.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $172.61 | $104.16 | -40% |
| Pro Medicus Limited PME | A$161.58 | A$33.82 | -79% |
| BrightSpring Health Services, Inc BTSG | $67.20 | $26.39 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.92 | $56.63 | -33% |
| M3, Inc MTHRY | $5.20 | $5.32 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Diaceutics PLC (DXRX) undervalued?
What is the fair value of DXRX?
What is the quality score of DXRX?
What is the revenue of Diaceutics PLC (DXRX)?
What is the net profit margin of DXRX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.